The investable signal is an inflection in adoption quality, not just top-line growth. In single-use endoscopy, once clinicians standardize around disposable workflows, the revenue stream becomes recurring and the economics improve quickly with factory utilization, so incremental volume can translate into disproportionate margin leverage. That makes AMBFF less a one-quarter story and more a proof point that the category is moving from skepticism to institutionalized purchasing.

The main losers are the legacy reusable-endoscopy franchises and the reprocessing ecosystem, where the pain is second-order: lower procedure share reduces utilization of installed bases and weakens bargaining power in service contracts. If respiratory is the beachhead, the spillover matters because hospitals tend to adopt common infection-control protocols across departments; however, bigger medtech competitors can respond by bundling capital equipment and pricing aggressively, which could cap the duration of supernormal economics.

Near term, the stock should trade on whether this is a durable acceleration or a one-off quarter. The key falsifiers over the next 1-2 quarters are gross margin slippage, signs of hospital budget tightening, or commentary that adoption is concentrating in one segment rather than broadening. Longer term, the consensus may be underestimating how sticky reusable economics remain outside respiratory, so extrapolating this into a multi-year share-gain run without proof in adjacent procedures looks premature.